Preferences for different methods of communicating information regarding adjuvant chemotherapy for breast cancer
- PMID: 15580617
- DOI: 10.1002/pon.886
Preferences for different methods of communicating information regarding adjuvant chemotherapy for breast cancer
Abstract
Many patients play an active role in determining their cancer treatments, and the communication of medical information influences patient decision-making. This study examined participants' preferences between various methods of communicating quantitative risks and benefits of adjuvant chemotherapy. Using clinical vignettes, participants were first asked to decide whether or not to endorse chemotherapy and were subsequently asked about their preferences for the methods used to communicate the risks and benefits. Participants preferred the absolute survival benefit method over negatively framed methods, such as relative or absolute risk reduction. We also present analysis of qualitative data which supports the conclusions drawn from quantitative analyses. In summary, the absolute survival benefit was shown to be the superior method of communicating quantitative risks and benefits of chemotherapy. Failure to use clear and concise methods of communicating quantitative risk and benefit information may compromise efforts to obtain informed consent for treatment.
Copyright (c) 2004 John Wiley & Sons, Ltd.
Similar articles
-
Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.J Clin Oncol. 2003 Dec 1;21(23):4299-305. doi: 10.1200/JCO.2003.06.025. Epub 2003 Oct 27. J Clin Oncol. 2003. PMID: 14581440
-
A qualitative study of factors affecting chemotherapy use in older women with breast cancer: barriers, promoters, and implications for intervention.Psychooncology. 2006 Dec;15(12):1065-76. doi: 10.1002/pon.1042. Psychooncology. 2006. PMID: 16598833
-
Factors affecting patients' perceptions of choice regarding adjuvant chemotherapy for breast cancer.Breast Cancer Res Treat. 2006 Sep;99(1):35-45. doi: 10.1007/s10549-006-9178-z. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541318
-
Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.Eur J Cancer. 2007 Jul;43(10):1514-28. doi: 10.1016/j.ejca.2007.03.017. Epub 2007 May 4. Eur J Cancer. 2007. PMID: 17482454 Review.
-
Physician/patient decision aids for adjuvant therapy.J Clin Oncol. 2005 Mar 10;23(8):1627-30. doi: 10.1200/JCO.2005.10.072. J Clin Oncol. 2005. PMID: 15755969 Review. No abstract available.
Cited by
-
Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.Med Decis Making. 2010 Jul-Aug;30(4):464-73. doi: 10.1177/0272989X09360371. Epub 2010 Feb 16. Med Decis Making. 2010. PMID: 20160070 Free PMC article.
-
Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment.J Oncol Pract. 2016 Jun;12(6):e613-25. doi: 10.1200/JOP.2015.008508. Epub 2016 May 10. J Oncol Pract. 2016. PMID: 27165488 Free PMC article.
-
Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods.Qual Life Res. 2020 Jul;29(7):1747-1766. doi: 10.1007/s11136-020-02503-8. Epub 2020 Apr 24. Qual Life Res. 2020. PMID: 32333238 Free PMC article.
-
Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer.JNCI Cancer Spectr. 2018 Nov 27;2(4):pky037. doi: 10.1093/jncics/pky037. eCollection 2018 Oct. JNCI Cancer Spectr. 2018. PMID: 31360867 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical